2021
Sa302 IS MULTIFOCALITY IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS A RISK FACTOR FOR PANCREATIC MALIGNANCY?: A SYSTEMATIC REVIEW AND META-ANALYSIS
Chhoda A, Singh S, Grimshaw A, Sheth A, Sharma A, Kunstman J, Ahuja N, Farrell J. Sa302 IS MULTIFOCALITY IN INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS A RISK FACTOR FOR PANCREATIC MALIGNANCY?: A SYSTEMATIC REVIEW AND META-ANALYSIS. Gastroenterology 2021, 160: s-477. DOI: 10.1016/s0016-5085(21)01845-x.Peer-Reviewed Original Research
2018
Genomics of Peritoneal Malignancies
Karunasena E, Sham J, McMahon KW, Ahuja N. Genomics of Peritoneal Malignancies. Surgical Oncology Clinics Of North America 2018, 27: 463-475. PMID: 29935683, DOI: 10.1016/j.soc.2018.02.004.Peer-Reviewed Original ResearchConceptsPeritoneal malignancyPeritoneal metastasisSimilar genetic mutationsEpithelial-mesenchymal transitionBiologic therapySurgical resectionMetastatic lesionsPredictive markerPrimary tumorIntraabdominal organsAggressive cancerMultiple cancersMetastasisMalignancyGenetic mutationsCancerOrgansResectionChemotherapyPeritoneumTherapyLesionsTumorsAbdomenAdjunct
2017
Circulating Epithelial Cells in Intraductal Papillary Mucinous Neoplasms and Cystic Pancreatic Lesions
Poruk KE, Valero V, He J, Ahuja N, Cameron JL, Weiss MJ, Lennon AM, Goggins M, Wood LD, Wolfgang CL. Circulating Epithelial Cells in Intraductal Papillary Mucinous Neoplasms and Cystic Pancreatic Lesions. Pancreas 2017, 46: 943-947. PMID: 28697136, DOI: 10.1097/mpa.0000000000000869.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPapillary mucinous neoplasmBlood of patientsEpithelial cellsMucinous neoplasmsPancreatic lesionsAbsence of malignancyBenign pancreatic lesionsCystic pancreatic lesionsNineteen patientsPancreatic resectionPeripheral bloodPancreatic cystsISET methodPatientsPancreas-specific markersResectionMalignancyDysplasiaBloodNeoplasmsPancreatic sourceLow gradeLesionsGenomics of peritoneal surface malignancies
Singh J, Sharma A, Ahuja N. Genomics of peritoneal surface malignancies. Journal Of Peritoneum (and Other Serosal Surfaces) 2017, 2 DOI: 10.4081/joper.2017.62.Peer-Reviewed Original ResearchPeritoneal malignancyHyperthermic intraperitoneal chemotherapyPeritoneal surface malignanciesLong-term survivalPrediction of responseAppendiceal neoplasmsIntraperitoneal chemotherapySurface malignanciesPeritoneal mesotheliomaPeritoneal metastasisPseudomyxoma peritoneiAggressive cytoreductionColorectal cancerTargeted therapyTerminal diseaseTherapeutic markersClinical decisionMalignancyClinical therapyTherapyGenomic alterationsMetastasisGenomic anomaliesGenomic characterizationCytoreductionEpigenetic therapy and chemosensitization in solid malignancy
Ronnekleiv-Kelly SM, Sharma A, Ahuja N. Epigenetic therapy and chemosensitization in solid malignancy. Cancer Treatment Reviews 2017, 55: 200-208. PMID: 28431263, DOI: 10.1016/j.ctrv.2017.03.008.Peer-Reviewed Original ResearchConceptsCombination therapyEpigenetic therapySpecific hematologic malignanciesCertain solid tumorsHistone deacetylase inhibitorsDurable responsesSystemic therapyPatient subsetsSolid malignanciesHematologic malignanciesOvarian cancerBreast cancerDNA methyltransferase inhibitorEpigenetic changesSolid tumorsDeacetylase inhibitorsStandard chemotherapeuticsTherapyClinical potentialCancer cellsTrialsNSCLCMalignancyMethyltransferase inhibitorHypermethylation patterns
2014
High-dose-rate intraoperative radiation therapy: the nuts and bolts of starting a program
Moningi S, Armour EP, Terezakis SA, Efron JE, Gearhart SL, Bivalacqua TJ, Kumar R, Le Y, Ng S, Wolfgang CL, Zellars RC, Ellsworth SG, Ahuja N, Herman JM. High-dose-rate intraoperative radiation therapy: the nuts and bolts of starting a program. Journal Of Contemporary Brachytherapy 2014, 6: 99-105. PMID: 24790628, PMCID: PMC4003434, DOI: 10.5114/jcb.2014.42027.Peer-Reviewed Original ResearchRate intraoperative radiation therapyIntraoperative radiation therapyRadiation therapyLocal controlGroup of patientsEffective local controlPelvic solid tumorsHDR-IORTRecurrent tumorsTrue efficacySolid tumorsMultidisciplinary approachPatientsTherapyTumorsIORT programProper administrationIORTSpecialized institutionsMalignancyOncologistsAnesthesiologistsPhysics staffNursesSurgeonsCpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas
Sun L, Guzzetta AA, Fu T, Chen J, Jeschke J, Kwak R, Vatapalli R, Baylin SB, Iacobuzio-Donahue CA, Wolfgang CL, Ahuja N. CpG island methylator phenotype and its association with malignancy in sporadic duodenal adenomas. Epigenetics 2014, 9: 738-746. PMID: 24518818, PMCID: PMC4063833, DOI: 10.4161/epi.28082.Peer-Reviewed Original ResearchConceptsCpG island methylator phenotypeSporadic duodenal adenomasDuodenal adenomasBRAF mutationsVillous typeMethylator phenotypeCIMP-high statusPeriampullary locationAggressive managementDuodenal adenocarcinomaClinicopathologic featuresColorectal cancerColorectal adenomasKRAS mutationsHigh riskAdenomasMLH1 methylationCIMP statusCancerous lesionsOlder ageP16 methylationTumorsMalignancyInfrequent eventRole of methylation